Trial Profile
A Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Dialysis Subjects With Renal Anemia Who Are Not Treated With Erythropoiesis-Stimulating Agents (ESAs)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Molidustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms MIYABI HD-C
- Sponsors Bayer
- 11 Dec 2018 Status changed from active, no longer recruiting to completed.
- 21 Sep 2018 Planned End Date changed from 17 Nov 2019 to 27 Nov 2018.
- 21 Sep 2018 Planned primary completion date changed from 13 Oct 2019 to 30 Oct 2018.